Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IGT ((VSE:IGT) Blockbuster Anti-Cancer Test Results !!! -- Ignore unavailable to you. Want to Upgrade?

To: David Culver who wrote (35)	1/29/1998 1:46:00 PM
From: Flea	Read Replies (1) \| Respond to of 94

Thanks, Dave...here's the NR... IGT Pharma Inc - Meeting with health protection branch scheduled IGT Pharma Inc IGT Shares issued 7775915 1998-01-27 close $0.86 Wednesday Jan 28 1998 Mr Bruce Schmidt reports The company's clinical development group will be meeting with the Canadian Health Protection Branch in early February to discuss the investigational new drug (IND) application for the new anti-cancer drug candidate, anhydrovinblastine. The objective of this pre-IND meeting will be to confirm the parameters relating to quality control, safety and clinical protocols that will form the basis of an application to commence human clinical trials. IGT's current understanding of its regulatory schedule shows the basis of an IND application completed before the end of the first quarter with clinical trials scheduled near mid-year. At the same time, similar plans are underway for an IND submission to the US FDA. The focus of the human clinical trials for AVLB will be to provide the necessary safety and efficacy data that will allow for eventual marketing approval. At this time, the primary indications for use are non-small cell lung cancer (most commonly related to smoking) and certain gynecological cancers.